| 发明名称 |
TREATMENT OF T-CELL MEDIATED DISEASES |
| 摘要 |
The present invention relates to the discovery that certain adverse inflammatory responses, allergic diseases, undesired immune responses including transplan t rejection and autoimmune disease, and other disease states, can be treated or prevented by modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3.beta. (macrophage inflammatory protein-3b), to immune system T cells and dendritic cells. The present invention is also related to methods for screening for therapeutic compounds useful in the treatment of SLC mediated and MIP-3.beta. mediated disorders, and to the compounds detected by such screens. Appropriate assay methodology is also disclosed.</ SDOAB>
|
| 申请公布号 |
CA2383469(A1) |
申请公布日期 |
2002.10.30 |
| 申请号 |
CA20022383469 |
申请日期 |
2002.04.26 |
| 申请人 |
PFIZER PRODUCTS INC., |
发明人 |
MARTIN, WILLIAM HOLT;GLADUE, RONALD P.;POSS, CHRISTOPHER STANLEY |
| 分类号 |
A61K31/428;A61K31/5415;A61K45/00;A61P1/04;A61P1/16;A61P1/18;A61P3/10;A61P9/10;A61P9/14;A61P11/00;A61P11/02;A61P11/06;A61P13/12;A61P17/00;A61P17/06;A61P19/02;A61P21/00;A61P25/28;A61P27/02;A61P27/16;A61P29/00;A61P31/00;A61P31/06;A61P31/08;A61P31/16;A61P31/18;A61P35/00;A61P35/04;A61P37/02;A61P37/06;A61P37/08;A61P43/00;C07D417/12;C07D419/12;G01N33/15;G01N33/50;G01N33/566;G01N33/68;(IPC1-7):G01N33/567;G01N33/53;G01N33/563 |
主分类号 |
A61K31/428 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
